GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (FRA:D05) » Definitions » PB Ratio

Deciphera Pharmaceuticals (FRA:D05) PB Ratio : 3.43 (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Deciphera Pharmaceuticals's share price is €13.70. Deciphera Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was €4.00. Hence, Deciphera Pharmaceuticals's PB Ratio of today is 3.43.

The historical rank and industry rank for Deciphera Pharmaceuticals's PB Ratio or its related term are showing as below:

FRA:D05' s PB Ratio Range Over the Past 10 Years
Min: 1.23   Med: 3.52   Max: 6.56
Current: 3.35

During the past 9 years, Deciphera Pharmaceuticals's highest PB Ratio was 6.56. The lowest was 1.23. And the median was 3.52.

FRA:D05's PB Ratio is ranked worse than
73.18% of 962 companies
in the Drug Manufacturers industry
Industry Median: 1.945 vs FRA:D05: 3.35

During the past 12 months, Deciphera Pharmaceuticals's average Book Value Per Share Growth Rate was -13.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -22.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -14.50% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Deciphera Pharmaceuticals was 18.70% per year. The lowest was -22.70% per year. And the median was -16.55% per year.

Back to Basics: PB Ratio


Deciphera Pharmaceuticals PB Ratio Historical Data

The historical data trend for Deciphera Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals PB Ratio Chart

Deciphera Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only 5.98 5.72 1.78 3.09 3.71

Deciphera Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.09 2.59 2.70 2.69 3.71

Competitive Comparison of Deciphera Pharmaceuticals's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deciphera Pharmaceuticals's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's PB Ratio falls into.



Deciphera Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Deciphera Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=13.70/3.997
=3.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Deciphera Pharmaceuticals  (FRA:D05) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Deciphera Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Deciphera Pharmaceuticals (FRA:D05) Business Description

Traded in Other Exchanges
Address
200 Smith Street, Waltham, MA, USA, 02451
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Deciphera Pharmaceuticals (FRA:D05) Headlines

No Headlines